undamentalytics Newsletter
Sign in

Myriad Genetics Inc cash flow statement

In fiscal 2025, Myriad Genetics Inc's operations generated $1.8m of cash; it spent $0 on capital projects, leaving free cash flow of $1.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Jun 20092010Jun 20102011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations84155131142174190141166106116846119−106−111−928
Depreciation and amortisation9779914252748547372635362615435
Stock-based pay262325262727463230273425363841503529
Capital spending884911142456891018450000
Free cash flow7714712713216217611716110010875511−152−111−928
Free cash flow after stock pay511241021061361497113070804225−36−190−152−59−33−21
Share buybacks—712001281462882111633205000—————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IRTC vs MYGNMYGN vs OFIXATEC vs MYGN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Myriad Genetics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Myriad Genetics Inc.